CBD
Cannabidiol · CBD · Discovered 1940
Comprehensive guide to CBD (Cannabidiol), the non-psychoactive cannabinoid used for anxiety, pain, seizures, and inflammation. Explore research, benefits, dosing, and legal status.
Psychoactive
No
Discovered
1940
Effects
9 documented
Benefits
5 studied
Overview
Cannabidiol (CBD) is the second most abundant cannabinoid in cannabis and the most prevalent in hemp varieties. First isolated in 1940 by American chemist Roger Adams, CBD has become one of the most intensively studied natural compounds in modern pharmacology. Unlike THC, CBD does not produce intoxicating effects, making it appealing for patients and consumers seeking therapeutic benefits without cognitive impairment. The 2018 Farm Bill legalized hemp-derived CBD in the United States, triggering an explosion in consumer products ranging from oils and capsules to topicals and beverages.
CBD's therapeutic profile is remarkably broad, with demonstrated efficacy in epilepsy, anxiety disorders, chronic pain, inflammation, and neurodegenerative conditions. In 2018, the FDA approved Epidiolex, a purified CBD formulation, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome — two severe forms of childhood epilepsy. This marked the first FDA approval of a cannabis-derived medication and validated decades of research into CBD's anticonvulsant properties. Clinical trials showed that Epidiolex reduced seizure frequency by up to 40% compared to placebo.
The global CBD market has grown rapidly, reaching an estimated $7.7 billion in 2024. However, the regulatory landscape remains complex, with the FDA yet to establish a comprehensive framework for CBD in food and dietary supplements. Quality and labeling accuracy vary significantly among CBD products, with studies finding that up to 70% of products tested contained different CBD concentrations than advertised.
Mechanism of Action
CBD has a complex, multi-target pharmacology that distinguishes it from most other cannabinoids. Unlike THC, CBD has very low affinity for CB1 and CB2 receptors and instead acts as a negative allosteric modulator of CB1, potentially reducing THC's binding efficiency and moderating its psychoactive effects. CBD activates serotonin 5-HT1A receptors, which is believed to underlie its anxiolytic and antidepressant effects. It also acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission and contributing to its anti-anxiety and anticonvulsant properties. CBD inhibits the reuptake of the endocannabinoid anandamide by blocking the FAAH enzyme, thereby increasing endocannabinoid tone. Additional targets include TRPV1 vanilloid receptors (pain perception), PPARgamma nuclear receptors (anti-inflammatory), GPR55 orphan receptors, and adenosine receptors (anti-inflammatory, cardiovascular).
Therapeutic Effects
Potential Benefits
Epilepsy (Dravet & Lennox-Gastaut Syndromes)
Conclusive evidence. FDA-approved Epidiolex reduced seizure frequency by 36-40% in Phase III trials. Multiple randomized controlled trials with hundreds of patients demonstrate robust anticonvulsant efficacy.
Anxiety Disorders
Strong evidence. A 2019 study in The Permanente Journal found that 79.2% of patients reported improved anxiety scores with CBD. Multiple RCTs show CBD reduces anxiety in social anxiety disorder, generalized anxiety, and PTSD-related anxiety at doses of 300-600mg.
Chronic Pain and Inflammation
Moderate evidence. Preclinical studies consistently demonstrate anti-inflammatory effects through multiple pathways. Human studies show benefit for neuropathic pain and arthritis. CBD topicals show promise for localized pain and inflammation.
Insomnia
Moderate evidence. Studies suggest CBD at higher doses (160mg+) may improve sleep duration and quality. A 2019 case series found 66.7% of patients reported improved sleep within the first month of CBD use.
Substance Use Disorders
Emerging evidence. Preliminary trials suggest CBD may reduce cravings in opioid, cocaine, and tobacco dependence. A 2019 study in the American Journal of Psychiatry found CBD reduced cue-induced craving and anxiety in heroin-abstinent individuals.
Side Effects & Risks
- ⚠Fatigue and drowsiness, especially at higher doses
- ⚠Diarrhea and gastrointestinal discomfort
- ⚠Changes in appetite and weight
- ⚠Drug interactions — CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2D6), potentially affecting metabolism of other medications
- ⚠Dry mouth
- ⚠Potential liver enzyme elevation at very high doses (observed in Epidiolex trials)
- ⚠Reduced blood pressure (hypotension)
Concentration & Sources
Typical Concentration
0.5-25% in cannabis flower; up to 20% in hemp flower; 250-5000mg per bottle in CBD oils; 10-50mg per serving in edibles
Found In
High-CBD cannabis strains (ACDC, Charlotte's Web, Harlequin, Cannatonic, Ringo's Gift), hemp cultivars, and a wide range of commercial CBD products including oils, capsules, topicals, gummies, and beverages.
Legal Status
Federally legal in the United States when derived from hemp containing less than 0.3% THC (2018 Farm Bill). FDA-approved as Epidiolex for certain seizure disorders. Legal in most countries worldwide when derived from hemp.
Research Summary
CBD is one of the most researched cannabinoids with over 3,000 published studies. The FDA approval of Epidiolex in 2018 represented a landmark validation of cannabinoid medicine. Research has expanded dramatically across multiple therapeutic areas. Large-scale clinical trials are currently investigating CBD for schizophrenia, autism spectrum disorder, Parkinson's disease tremor, and graft-versus-host disease. A major area of ongoing research is CBD's potential neuroprotective properties, with preclinical evidence suggesting benefit in models of Alzheimer's disease, multiple sclerosis, and traumatic brain injury. The World Health Organization concluded in 2017 that CBD exhibits no effects indicative of abuse or dependence potential, and recommended it not be internationally scheduled. Despite the growing body of evidence, regulatory challenges persist, particularly regarding standardization, quality control, and appropriate dosing guidelines for various conditions.
Related Cannabinoids
CBD FAQ
Does CBD get you high?
No, CBD does not produce a psychoactive high. Unlike THC, CBD has very low affinity for CB1 receptors in the brain and does not produce euphoria, altered perception, or intoxication. CBD may actually reduce the intensity of THC's psychoactive effects when the two cannabinoids are consumed together, acting as a negative allosteric modulator of the CB1 receptor.
Will CBD show up on a drug test?
Pure CBD should not cause a positive drug test, as standard tests screen for THC metabolites (THC-COOH), not CBD. However, many full-spectrum CBD products contain trace amounts of THC (up to 0.3% in hemp-derived products), which could potentially accumulate with heavy daily use and trigger a positive result. To minimize this risk, consumers can choose broad-spectrum or CBD isolate products that contain no detectable THC.
How much CBD should I take?
CBD dosing varies significantly by condition, individual body chemistry, and product type. General guidelines suggest starting with 10-25mg per day and gradually increasing over 1-2 weeks. For anxiety, clinical studies have used doses of 300-600mg. For epilepsy, Epidiolex is dosed at 5-20mg/kg/day. For general wellness, 25-50mg daily is common. Always consult a healthcare provider, especially if taking other medications, as CBD can interact with drugs metabolized by cytochrome P450 enzymes.
Is CBD legal everywhere?
Hemp-derived CBD containing less than 0.3% THC is federally legal in the United States under the 2018 Farm Bill, but some states have additional restrictions. In Europe, CBD regulations vary by country — it is widely available in the UK, Germany, and most EU nations, though THC limits and novel food regulations differ. CBD derived from marijuana (containing more than 0.3% THC) follows marijuana laws in each jurisdiction. Always check local regulations before purchasing or traveling with CBD products.
What is the difference between full-spectrum, broad-spectrum, and CBD isolate?
Full-spectrum CBD contains all cannabinoids naturally present in the plant, including up to 0.3% THC, plus terpenes and flavonoids. Broad-spectrum CBD undergoes additional processing to remove THC while retaining other cannabinoids and terpenes. CBD isolate is 99%+ pure CBD with no other plant compounds. Full-spectrum products may offer enhanced benefits through the entourage effect, where multiple cannabis compounds work synergistically, but broad-spectrum and isolate are preferred by those who want to avoid any THC exposure.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.